http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
-
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
-
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
-
Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
-
Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer
-
Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results
-
Sema4 Announces Changes to its Research & Development Leadership
-
Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
-
Sema4 (SMFR) CFO Isaac Ro to Resign, Richard Miao Named Interim CFO
-
Sema4 Announces Chief Financial Officer Transition Plan
-
Avera Health and Sema4 Announce Data-driven Study to Advance Cancer Treatment Across the Avera Service Area
-
Sema4 to Participate at Two Investor Conferences in June 2022
-
Sema4 Reports First Quarter 2022 Financial Results and Business Highlights
-
Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
-
Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
-
Sema4 Achieves HITRUST CSF Certification
-
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
-
Sema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved Communities
-
Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
-
Sema4 Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
-
Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022
-
Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine
-
Sema4 to Participate at Two Upcoming Investor Conferences in February
-
Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities
-
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
-
Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021
-
Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January
-
Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights
-
Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction
-
Sema4 to Participate at Three Upcoming Investor Conferences in November
-
Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
-
Sema4 Appoints Computational Biology Expert Gustavo Stolovitzky as Chief Science Officer
-
Sema4 Launches Sema4 Elements™, a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health
-
Sema4 to Participate at Two Upcoming Investor Conferences in September
-
Sema4 Reports Second Quarter 2021 Financial Results and Business Highlights
-
Avera Health and Sema4 Announce Collaboration to Advance Precision Oncology Care
-
Sema4 to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
-
Sema4 to Participate at Two Upcoming Investor Conferences in August
-
Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company
